IXI™ (Version 10) advances data processing speed and volume
12 May 2026, IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced the latest version release (v.10) of IXI™, IXICO’s proprietary AI enabled neuroimaging platform that delivers clinical trial imaging and biomarker insights in neurological disease research.
The IXI™ 10.0 release brings advances in image reading precision and analysis, enables larger and faster image data processing, and integrates new tools for remote image access and data quality qualification. The latest generation of IXI™ lays the foundation for IXICO’s technology to move beyond its traditional iCRO remit as part of the Group’s TechBio strategy. The strategy is focused on increasing IXICO’s addressable market by enabling external organisations to directly access IXICO's technology via licensing, technology integration and partnering models such as the recently announced collaboration with Medidata (26 March 2026).
About IXI™
Designed by neuroscience and data science experts, the IXI™ Platform is a proprietary suit of technologies and AI tools tailor-made for neurological disease complexity. IXI™ uses machine learning and deep learning to reliably process data from global trials and build algorithms that precisely measure key imaging biomarkers associated with the identification, progression and treatment of Alzheimer’s, Parkinson’s, Huntington’s and other rare neurological diseases. It is the only technology platform of its kind specifically built for, and exclusively focussed on, neuroimaging processing and neurological biomarker analysis.
IXI™ is being used every day across the world. With over 30 cutting edge analytics algorithms the Platform integrates standardised high quality image data capture, image reading, advanced analysis and regulatorily compliant reporting of clinical data. IXI™ supports the biopharma industry to develop new medicines and diagnostic measures, informing decisions earlier in the drug development process via a single end to end platform.
Bram Goorden, Chief Executive Officer of IXICO, commented: “As the field of CNS is rapidly embracing precision medicine, the players in clinical development need technologies that deliver faster, more scalable and highly precise biomarker insights. The latest generation of our AI-driven technology platform IXI™ hosts some of the most advanced algorithms in neurodegenerative disease, increases accuracy and processing capacity and further strengthens data quality oversight, all while simplifying user interaction and integration in established partner platforms. This all with one objective in mind : helping biopharma make earlier and better-informed decisions.”
